News

February 11, 2019

Losartan May Improve Ovarian Cancer Treatment, Study Finds

News

Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Patients with ... Read more

February 8, 2019

IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA

News

IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company now ... Read more

February 6, 2019

Bavencio Shows Promise in Heavily Treated Ovarian Cancer Patients in Phase 1b Trial

News

Immune checkpoint inhibitor Bavencio (avelumab) has an acceptable safety profile and shows some anti-tumor activity among heavily pretreated ovarian cancer patients, according to a Phase 1b trial. Findings from the trial were reported ... Read more

February 4, 2019February 6, 2019

Phase 1 Trial Testing IMV’s Tailored Immunotherapy Doses First Ovarian Cancer Patient

News

IMV’s Phase 1 clinical trial evaluating a personalized immunotherapy that targets mutated proteins called neoepitopes in ovarian cancer patients has started dosing participants, the company announced. “The first immunization of the ... Read more

February 1, 2019

Alisertib-Taxol Combo Shows Promise in Recurrent Ovarian Cancer

News

A combination of the investigational treatment alisertib and weekly Taxol (paclitaxel) showed promising anti-tumor activity in ovarian cancer patients treated in a Phase 1/2 trial, warranting further studies of the combination. ... Read more

January 30, 2019

Rubraca Maintenance Approved in Europe for Relapsed Ovarian Cancer

News

The European Commission has extended Rubraca‘s (rucaparib) approval as a maintenance therapy for women with advanced, relapsed ovarian cancer who are in complete or partial response to platinum-based chemotherapy. This recent ... Read more

January 28, 2019

Report: Imported Liposomal Doxorubicin Yields Similar Outcomes as Approved OC Formulation

News

A non-approved formulation of pegylated liposomal doxorubicin — called Lipodox — seems to lead to similar response rates and time to disease progression in ovarian cancer patients as the approved Doxil formulation, ... Read more

January 25, 2019

Phase 3 Trial of Bavencio in Ovarian Cancer is Terminated

News

The immune checkpoint inhibitor Bavencio (avelumab) — given in combination and/or after platinum-based chemotherapy — is no better than chemotherapy alone at delaying disease progression or death in previously untreated women with ... Read more

January 23, 2019

Researchers Use Stem Cells to Produce Cancer-targeting Antibodies

News

In a new study, researchers have used stem cell proteins to create an antibody that can specifically recognize and be taken up by some types of breast and ovarian cancers. ... Read more

January 21, 2019

Phase 1b/2 Trial of AVB-S6-500 for Platinum-resistant Recurrent OC Begins

News

The first part of a Phase 1b/2 trial evaluating the combination of Aravive Biologics’ investigational therapy AVB-S6-500 with standard-of-care therapies in patients with platinum-resistant recurrent ovarian cancer has begun treating ... Read more